The US corporation Johnson & Johnson (J&J) faces lower operating profits this year after acquiring the medical device developer V-Wave. Despite these challenges, revenue exceeded expectations, offering a nuanced picture of the pharmaceutical and medical technology group.

In the third quarter, J&J's revenue increased by about five percent to just under 22.5 billion US dollars (approximately 20.8 billion euros), exceeding market expectations. Although the adjusted earnings per share (EPS) fell by nine percent to 2.42 US dollars, it surpassed the analysts' estimates of 2.19 US dollars. This decline is mainly due to higher costs incurred from the acquisition of V-Wave. Additionally, the company recorded a revenue increase of 7 percent to 6.438 billion euros, meeting the expectations of 6.4 billion euros.

The acquisition of V-Wave for $1.7 billion fits into J&J's strategic realignment, which separated from its consumer goods division last year. The focus is now on more profitable business areas such as prescription drugs and medical devices. In addition to V-Wave, J&J recently acquired heart device manufacturer Shockwave Medical for $13.1 billion to further strengthen its position in the medical technology market.

The cancer drug Darzalex developed particularly positively, exceeding industry experts' expectations and contributing to increased sales. These results underscore the successful integration of new acquisitions and the solid performance of the company's core segments.

Despite Better Operating Business, Lowering of Full-Year Profit Forecast Leads to Negative Reaction from Investors

The Johnson & Johnson stock reacted accordingly to the changed expectations and lost 7.24 percent at times in NYSE trading, closing at 561.59 USD. Despite these losses, J&J remains a key player in the global pharmaceutical and medical technology market, continuing its strategic investments to ensure long-term growth and stability.